$GH News
Last published 4h ago
- 4h agoGHGuardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032Business WirePALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A u ...
- 11h agoGHGuardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® LiquidBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient’s cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients ...
- 1d agoGHPRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer MetastasesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorec ...
- 2d agoGHGuardant Health to Participate in Upcoming Investor ConferencesBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fir ...
- 6d agoGHGuardant Health Q3 2026 Earnings Call - GUARDANT HEALTH INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Garden Health third quarter 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question
- 6d agoGHGuardant Health, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoGHGuardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for PennsylvaniansBusiness WireTwo million more screening-eligible Pennsylvanians will now have access to the Shield blood test for colorectal cancer (CRC) with no cost-sharingGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company,
- 3w agoGHGuardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026Business WireResearch reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification Presentations reflect Guardant’s strong
- 3w agoGHTwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 PatentBusiness WireFollowing Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health TwinStrand Biosciences (TwinStrand),
- 3w agoGHGuardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based TestsBusiness WireModeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing New data demonstrates notable screening adherence rate of 99%
- 1mo agoGHGuardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerBusiness WireGuardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies This latest approval marks Guardant’s 31st CDx approval Guardant Health, Inc.
- 1mo agoGHGuardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026Business WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management
- 1mo agoGHGuardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in MelanomaBusiness WireFirst published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity Molecular residual disease detection
- 1mo agoGHMorgan Stanley 24th Annual Global Healthcare Conference - GUARDANT HEALTH INCEarnings Call TranscriptsI think we can get started. Callum Tishmarsh here from the Life Sciences team at Morgan Stanley. Welcome to Day 2 of the Morgan Stanley Healthcare Conference. Really pleased today to be joined by the team at Garden Healt
- 1mo agoGHGuardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer ScreeningBusiness WireSecond largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Milestone marks rapid adoption by
- 2mo agoGHGuardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung CancerBusiness WireResearch highlights the significance of genomic and epigenomic profiling approaches to characterize lung tumors, identify biomarkers, and support risk stratification Real-world studies examine the complementary
- 2mo agoGHBusiness Insider Names Guardant Health One of America's Most Innovative BusinessesBusiness WireEarning the highest five-star recognition alongside only 12 other companies in the biotechnology category Recognition underscores Guardant’s leadership in precision oncology including patient growth and years of
- 2mo agoGHGuardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast CancerBusiness WireApproval recommends repeat Guardant360 CDx testing every three months during therapy to detect emerging ESR1 mutations before clinical or radiographic disease progressionIn the Phase III SERENA-6 trial, ctDNA-guided
- 2mo agoCRMSPGIGHSequoia-incubated Empirik launches with $21M to predict outages before they happenTechCrunch
- 2mo agoGHGuardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer ScreeningBusiness WireLargest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Increasing total covered Shield lives ages 45
- 2mo agoGHGuardant Health to Appeal Federal District Court JudgmentBusiness WireCurrent Guardant Reveal, Shield products excluded from final District Court order Company has validated Guardant360 design improvements to exclude impact of potential royalties Guardant Health, Inc. (NASDAQ:GH),
- 2mo agoGHTwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and InterestBusiness WireCourt preserves 2023 willful infringement verdict and orders a 6% royalty on sales of 11 Guardant Health products and services found to infringe two patents underlying TwinStrand Duplex Sequencing® technology Court
- 3mo agoGHCG 46TH ANNUAL GROWTH CONFERENCE - GUARDANT HEALTH INCEarnings Call TranscriptsWelcome to the Canaccord Genuity Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnostics for Canaccord. Really pleased to welcome you to a fireside chat with Garden Health here with us today. The co
- 3mo agoGHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock
- 3mo agoGHGuardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceBusiness WireSecond quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38% Guardant Health, Inc.
- 3mo agoGHGuardant Health to Participate in Upcoming Investor ConferencesBusiness WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in
- 3mo agoGHActor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal CancerBusiness WireDempsey is calling on Americans to prioritize getting screened and highlighting the innovative Shield blood test for CRC screening Guardant's Shield blood test is the only FDA-approved blood test included in
- 4mo agoGHGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026Business WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management
- 4mo agoGHUnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer ScreeningBusiness WireUpdated United policy coverage from the largest commercial insurer in the U.S. means 100 million total covered lives have access to the FDA-approved Shield blood test for colorectal cancer (CRC) screening Shield is
- 4mo agoGHCRMX now offers an MCP server to make its platform easier for AI tools to useTechCrunch
- 4mo agoGHANNUAL MEETING OF STOCKHOLDERS - GUARDANT HEALTH INCEarnings Call TranscriptsWelcome to the 2026 Annual Meeting of Stockholders for Garden Health, Inc. Please note, all participants will be in a listen-only mode. If you wish to ask a question, please submit your question via the designated field
- 5mo agoGHGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®Business WireBlood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets) Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today
- 5mo agoGHJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORKGUARDANT HEALTH INCEarnings Call TranscriptsThanks. We're going to kick it off. I'm Tycho Pearson for the Life Science team. It's my pleasure to introduce Garden. We've got Mike and Zarek with us today. Maybe to kick it off, Mike, I'll flip it over to you to just
- 5mo agoGHWilliam Blair 46th Annual Growth Stock Conference - GUARDANT HEALTH INCEarnings Call TranscriptsGood morning. Thanks for joining us here at the William Blair Growth Stock Conference. For those of you who don't know me, my name is Andrew Brackman. I lead the Diagnostics Equity Research Team here at William Blair. Th
- 5mo agoGHGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual MeetingBusiness WireNew performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying
- 5mo agoGHAmerican Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening GuidelinesBusiness WireUpdated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening Shield is the first and only FDA-approved blood test included
- 5mo agoGHFDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded FootprintBusiness WireGuardant Health's new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant's leadership
- 5mo agoGHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock
- 6mo agoGH2026 GLOBAL HEALTHCARE CONFERENCEGUARDANT HEALTH INCEarnings Call TranscriptsAll right. We'll kick things off. Thanks, everyone, for joining us for our next session. My name is Mike Riskin. I'm on the Bank of America Life Science Tools and Diagnostics team. And for our chat, we're excited to host
- 6mo agoGHPANWCRWDExaforce raises $125M Series B to build AI for catching and stopping cyberattacks as they happenTechCrunch
- 6mo agoGHGuardant Health Q1 2026 Earnings CallGUARDANT HEALTH INCEarnings Call TranscriptsGood afternoon. Thank you for attending the Garden Health Q1 2026 earnings call. My name is Matt, and I'll be the moderator for today's call. All lines will be muted during the presentation portion of the call for an opp
- 6mo agoGHGuardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceBusiness WireFirst quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34% Guardant Health, Inc.
- 6mo agoGHGuardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 MutationsBusiness WireBlood-based test enables identification of patients eligible for targeted treatment with VEPPANU™ Approval marks Guardant's third ESR1 companion diagnostic FDA approval to help guide timely treatment
- 6mo agoGHNUVLGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformBusiness WireMulti-year global collaboration will leverage Guardant's tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies Guardant Health, Inc. (NASDAQ:GH), a leading precision
- 6mo agoGHGuardant Health to Participate in Upcoming Investor ConferencesBusiness WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2026 Healthcare Conference in Las
- 6mo agoGHGuardant Health to Report First Quarter 2026 Financial Results on May 7, 2026Business WireGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will
- 7mo agoGHGuardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in JapanBusiness WireThis milestone underscores the power of Guardant Health's InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations Guardant Health, Inc. (NASDAQ:GH), a
- 7mo agoGHVerana Health and Guardant Health Partner to Advance Precision Medicine with Real-World DataPR NewswireVerana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced ...
- 7mo agoGHGuardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026Business WireGuardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong performance of Guardant360 Tissue in determining tissue of
- 8mo agoGHGuardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife PartnershipBusiness WirePartnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines Eligible Manulife customers in Hong Kong,